Development and Validation of the 5-SENSE Score to Predict Focality of the Seizure-Onset Zone as Assessed by Stereoelectroencephalography.


Journal

JAMA neurology
ISSN: 2168-6157
Titre abrégé: JAMA Neurol
Pays: United States
ID NLM: 101589536

Informations de publication

Date de publication:
01 01 2022
Historique:
pubmed: 7 12 2021
medline: 19 2 2022
entrez: 6 12 2021
Statut: ppublish

Résumé

Stereoelectroencephalography (SEEG) has become the criterion standard in case of inconclusive noninvasive presurgical epilepsy workup. However, up to 40% of patients are subsequently not offered surgery because the seizure-onset zone is less focal than expected or cannot be identified. To predict focality of the seizure-onset zone in SEEG, the 5-point 5-SENSE score was developed and validated. This was a monocentric cohort study for score development followed by multicenter validation with patient selection intervals between February 2002 to October 2018 and May 2002 to December 2019. The minimum follow-up period was 1 year. Patients with drug-resistant epilepsy undergoing SEEG at the Montreal Neurological Institute were analyzed to identify a focal seizure-onset zone. Selection criteria were 2 or more seizures in electroencephalography and availability of complete neuropsychological and neuroimaging data sets. For validation, patients from 9 epilepsy centers meeting these criteria were included. Analysis took place between May and July 2021. Based on SEEG, patients were grouped as focal and nonfocal seizure-onset zone. Demographic, clinical, electroencephalography, neuroimaging, and neuropsychology data were analyzed, and a multiple logistic regression model for developing a score to predict SEEG focality was created and validated in an independent sample. A total of 128 patients (57 women [44.5%]; median [range] age, 31 [13-58] years) were analyzed for score development and 207 patients (97 women [46.9%]; median [range] age, 32 [16-70] years) were analyzed for validation. The score comprised the following 5 predictive variables: focal lesion on structural magnetic resonance imaging, absence of bilateral independent spikes in scalp electroencephalography, localizing neuropsychological deficit, strongly localizing semiology, and regional ictal scalp electroencephalography onset. The 5-SENSE score had an optimal mean (SD) probability cutoff for identifying a focal seizure-onset zone of 37.6 (3.5). Area under the curve, specificity, and sensitivity were 0.83, 76.3% (95% CI, 66.7-85.8), and 83.3% (95% CI, 72.30-94.1), respectively. Validation showed 76.0% (95% CI, 67.5-84.0) specificity and 52.3% (95% CI, 43.0-61.5) sensitivity. High specificity in score development and validation confirms that the 5-SENSE score predicts patients where SEEG is unlikely to identify a focal seizure-onset zone. It is a simple and useful tool for assisting clinicians to reduce unnecessary invasive diagnostic burden on patients and overutilization of limited health care resources.

Identifiants

pubmed: 34870697
pii: 2786580
doi: 10.1001/jamaneurol.2021.4405
pmc: PMC8649918
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

70-79

Commentaires et corrections

Type : CommentIn

Auteurs

Alexandra Astner-Rohracher (A)

Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada.
Department of Neurology, Christian Doppler University Hospital, Centre for Cognitive Neuroscience Paracelsus Medical University Hospital Salzburg, affiliated Member of the Epicare Reference Network, Salzburg, Austria.

Georg Zimmermann (G)

Team Biostatistics and Big Medical Data, IDA Lab Salzburg, Paracelsus Medical University, Salzburg, Austria.

Tamir Avigdor (T)

Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada.

Chifaou Abdallah (C)

Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada.

Nirav Barot (N)

Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania.

Milan Brázdil (M)

Department of Neurology, Faculty of Medicine, Masaryk University and St Ann's University Hospital, Brno, Czech Republic.

Irena Doležalová (I)

Department of Neurology, Faculty of Medicine, Masaryk University and St Ann's University Hospital, Brno, Czech Republic.

Jean Gotman (J)

Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada.

Jeffery Alan Hall (JA)

Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada.

Kirsten Ikeda (K)

Dalhousie University and Hospital, Division of Neurology, Halifax, Nova Scotia, Canada.

Philippe Kahane (P)

CHU Grenoble-Alpes, Université Grenoble Alpes, Inserm, U1216, Grenoble Institut Neurosciences, Grenoble, France.

Gudrun Kalss (G)

Department of Neurology, Christian Doppler University Hospital, Centre for Cognitive Neuroscience Paracelsus Medical University Hospital Salzburg, affiliated Member of the Epicare Reference Network, Salzburg, Austria.

Vasileios Kokkinos (V)

Department of Neurosurgery, Massachusetts General Hospital, Boston.

Markus Leitinger (M)

Department of Neurology, Christian Doppler University Hospital, Centre for Cognitive Neuroscience Paracelsus Medical University Hospital Salzburg, affiliated Member of the Epicare Reference Network, Salzburg, Austria.

Ioana Mindruta (I)

Neurology Department, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.

Lorella Minotti (L)

CHU Grenoble-Alpes, Université Grenoble Alpes, Inserm, U1216, Grenoble Institut Neurosciences, Grenoble, France.

Mary Margaret Mizera (MM)

Department of Neurology, Northwestern University, Chicago, Illinois.

Irina Oane (I)

Neurology Department, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.

Mark Richardson (M)

Department of Neurosurgery, Massachusetts General Hospital, Boston.

Stephan U Schuele (SU)

Department of Neurology, Northwestern University, Chicago, Illinois.

Eugen Trinka (E)

Department of Neurology, Christian Doppler University Hospital, Centre for Cognitive Neuroscience Paracelsus Medical University Hospital Salzburg, affiliated Member of the Epicare Reference Network, Salzburg, Austria.
Neuroscience Institute, Christian Doppler University Hospital, Centre for Cognitive Neuroscience Paracelsus Medical University Hospital Salzburg, Salzburg, Austria.
Karl Landsteiner Institute for Neurorehabilitation and Space Neurology, Salzburg, Austria.
Department of Public Health, Health Services Research and Health Technology Assessment, University for Health Sciences, Medical Informatics and Technology (UMIT), Hall in Tirol, Austria.

Alexandra Urban (A)

Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania.

Benjamin Whatley (B)

Dalhousie University and Hospital, Division of Neurology, Halifax, Nova Scotia, Canada.

François Dubeau (F)

Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada.

Birgit Frauscher (B)

Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH